Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis - Quiz - MDSpire

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

Baptist Health Brain & Spine Care is enrolling patients with confirmed multiple sclerosis who are starting BRUMVI to track outcomes, safety, and patient experience over time in a real-world setting.

  • By

  • March 4, 2026

  • 2 min

Share

Original Source(s)

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

  • by

  • March 4, 2026

Related Content

Nuclear receptor PPARγ targets GPNMB to promote oligodendrocyte development and remyelination

De-escalating and discontinuing disease-modifying therapies in multiple sclerosis

The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis